Rifaximin

CAS 80621-81-4 21 current records 1 historicalSmall Molecule

Who holds supplier records for Rifaximin? 21 organisations hold a current record for Rifaximin: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 14 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (13), Italy (5), China (2) and South (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Rifaximin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/rifaximin

Reading the evidence

  • 21 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    13 of the 21 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 15 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Rifaximin expires 2 Oct 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (21)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Rifaximin. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Rifaximin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (14)

Certificates of Suitability on the EDQM register for Rifaximin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 17 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MSN LABORATORIES PRIVATE LIMITED SangareddyIN
CEP 2016-016 - Rev 02
Rifaximin, α-Form, Milled and Non-milled
Aug 2026—
ZHEJIANG MEDICINE CO., LTD. ShaoxingCN
CEP 2024-576 - Rev 00
Rifaximin
Jun 2026—
HETERO DRUGS LIMITED HyderabadIN
CEP 2025-067 - Rev 00
Rifaximin, α-Form
Jun 2026—
CKD BIO CORP. Ansan-SiKR
CEP 2023-387 - Rev 00
Rifaximin
Jun 2026Inspected Sept 2023
Italy, outside 3-year window
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2025-011 - Rev 00
Rifaximin, Alpha Form
Jun 2026—
LUPIN LIMITED MumbaiIN
CEP 2020-175 - Rev 01
Rifaximin, Micronised, non-micronised
Jan 2026—
LUOHE CHIEF PHARMACEUTICAL CO., LTD. Luohe CityCN
CEP 2021-420 - Rev 01
Rifaximin
Dec 2025—
GRANULES INDIA LIMITED HyderabadIN
CEP 2021-377 - Rev 02
Rifaximin, [RSA code] Process-II
Aug 2025—
OPTIMUS DRUGS PRIVATE LIMITED HyderabadIN
CEP 2025-071 - Rev 00
Rifaximin, Process-II
Jul 2025—
OLON S.P.A. RodanoIT
CEP 2019-125 - Rev 04
Rifaximin, Alpha Form
Jul 2025Inspected Mar 2025
Italy
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2024-415 - Rev 00
Rifaximin, α-Form
Jul 2025—
Cosma S.p.A. CiseranoIT
CEP 2022-368 - Rev 00
Rifaximin
Sept 2024Inspected Nov 2025
Italy
CAMBREX PROFARMACO MILANO S.R.L. PaulloIT
CEP 2020-435 - Rev 00
Rifaximin
Feb 2024Inspected Sept 2025
Italy
F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. Montecchio MaggioreIT
R1-CEP 2010-085 - Rev 01
Rifaximin, Form α
Oct 2018—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Rifaximin are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • PHARMACEUTICAL FINE CHEMICALS PFC BAHAMAS LTD
    Inactive DMF 12352 · filed Feb 1997

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Rifaximin). The latest listed patent expires 2 Oct 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Rifaximin is a broad-spectrum antibiotic used to treat certain types of bacterial infections in the gastrointestinal tract. It works by inhibiting bacterial RNA synthesis, leading to the elimination of harmful bacteria while preserving the normal gut flora.

Chemical identity

IUPAC name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
Canonical SMILES
C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C
InChIKey
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
Synonyms
Xifaxan API, l-105, nsc-758957, rifamycin l 105, rifaxidin, xifaxsan

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Rifamycin Antibacterial
Chemical structure
Rifamycins

Therapeutic areas

GastroenterologyInfectious Diseases

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Rifaximin?

21 organisations hold an active US FDA Type II Drug Master File or a CEP for Rifaximin: Granules India Limited (India), MSN Laboratories Private Limited (India), Sun Pharmaceutical Industries Limited (India), Zydus Lifesciences Limited (India), Alembic Pharmaceuticals Limited (India), APITORIA PHARMA PRIVATE LTD (India), CAMBREX PROFARMACO MILANO SRL (Italy) and FIS FABBRICA ITALIANA SINTETICI SPA (Italy), and 13 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Rifaximin Drug Master Files are active?

Granules India Limited (DMF 32351, 36125), MSN Laboratories Private Limited (DMF 28096, 28097), Sun Pharmaceutical Industries Limited (DMF 31537, 33833), Zydus Lifesciences Limited (DMF 35323, 35423), Alembic Pharmaceuticals Limited (DMF 41007), APITORIA PHARMA PRIVATE LTD (DMF 40858), CAMBREX PROFARMACO MILANO SRL (DMF 31114) and FIS FABBRICA ITALIANA SINTETICI SPA (DMF 15635) and 11 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Rifaximin records mean?

1 organisation has only inactive Type II DMFs for Rifaximin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Rifaximin have a European Certificate of Suitability?

Yes. 14 organisations hold a valid CEP for Rifaximin on the EDQM register, including MSN LABORATORIES PRIVATE LIMITED Sangareddy (IN), ZHEJIANG MEDICINE CO., LTD. Shaoxing (CN), HETERO DRUGS LIMITED Hyderabad (IN), CKD BIO CORP. Ansan-Si (KR), ALEMBIC PHARMACEUTICALS LIMITED Vadodara (IN) and LUPIN LIMITED Mumbai (IN) and 8 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Rifaximin?

Yes. The latest patent listed for an approved US product containing Rifaximin expires 2 Oct 2029, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Rifaximin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Rifaximin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.